

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of CNSX Issuer: Marapharm Ventures Inc. (the "Issuer").

Trading Symbol: MDM

Number of Outstanding Listed Securities: 75,616,923

Date: March 3, 2017

1. Marapharm continues to work toward its corporate goals, as outlined below:

- With regard to Nevada, the company is moving ahead with construction to accommodate the three medical licenses. The buildings were delivered on December 19<sup>th</sup> and 20<sup>th</sup>, 2016 and an additional 1.17 acres was purchased on December 29<sup>th</sup>, 2016 to meet the development requirements of the City of North Las Vegas. The Special Use permits have been granted and grading has begun.
- The Company is doing due diligence on regulations and licensing on two properties in California.
- The Company is reviewing the use of ACM (Automated Cannabis Machines) with regard to regulations in each State.
- With regard to Washington, the Company has decided to move ahead with the 13 acres and is working with the license holder on plans that will enhance the facility to bring it to maximum production.

2. Management continues to work toward its operational goals, as set out below:

- With regard to operations in Nevada, a timeline has been formulated and construction has commenced of the cultivation and processing facilities.
- With regard to Washington, the Company is working on designs to enhance the value of the assets acquired, with the purchase of new equipment and building improvements.
- Amendments will be made to our Health Canada application to comply with the new regulations (ACMPR), as well as maintaining its current application to process medical marijuana.

3. At this time the following new products or services are being offered:

- The Company has entered into an agreement with Moringa Cooperative Inc. in California for a medical marijuana delivery service and an investigation into the Nevada and Arizona markets is currently underway.

4. No products or services have been discontinued.

5. The Company has entered into the following marketing and consulting agreements:

- The Company has entered into a one year agreement with a media company to promote Marapharm and the medical marijuana sector to its audience.
- Several marketing and consulting agreements have been extended due to their success.
- The Company has diversified its business by entering into an agreement with a medical marijuana delivery service.

6. No contracts are set to expire or terminate. No financing previously announced has been cancelled.

7.

- a) Marapharm entered into a subscription agreement with Veritas Pharma Inc. on January 4<sup>th</sup>, 2017 to acquire 5 million units at a price of \$0.22c per unit for an investment of \$1,100,000.00. Each unit consists of one common share and one share purchase warrant. Each warrant will entitle Marapharm to acquire one additional share at a price of \$0.30c per share for a period of 18 months from the date of issuance. Veritas Pharma Inc. is a company engaged in medical cannabis research.
- b) Marapharm entered into a second subscription agreement with Veritas Pharma Inc. on January 4, 2017 to acquire 5 million share purchase warrants at a price of \$.05c for consideration of \$250,000.00.
- c) Marapharm Las Vegas, LLC paid \$111,150.00 for an additional 1.17 acres in Apex Business Park and have discharged the mortgage on the 4.9 acres.

8. Not applicable.

9. There are no new developments re: intangible products.

10. There are no new hiring's.

11. There are no labour disputes.

12. a) Marapharm was served with a notice of claim in small claims court by Armadillo Resources Inc. for the amount \$16,176.00, for unpaid rent. The Company intends to dispute the claim, as no contract was ever entered into with Armadillo Resources Inc. for the payment of rent. A Settlement Conference in the Provincial Small Claims Court has been set for March 15, 2017.

13. Other than regular billing, there is no indebtedness.

14. Provide details of any securities issued and options or warrants granted:

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	112,500	Exercise of Stock Options, Expire on March 8, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	211,500	Exercise of Warrants Expire on April 14, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	2,746,670	Exercise of Warrants Expired on January 19, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	30,000	Exercise of Warrants Expire on June 17, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes

Common Shares	591,750	Exercise of Warrants Expire on September 6, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	500,000	Exercise of Stock Options, Expire on, May 8, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	200,000	Exercise of Stock Options, Expire on, September 24,2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	200,000	Exercise of Stock Options, Expire on, September 16, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	200,000	Exercise of Stock Options, Expire on, September 24, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
Common Shares	25,000	Exercise of Stock Options, Expire on, September 9, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes

---

**FORM 7 – MONTHLY PROGRESS REPORT**

March 3, 2017

Page 4

Common Shares	1,500,000	Exercise of Stock Options, Expire on, September 19, 2017	The proceeds will be used for the development of the Washington and Nevada projects and for general corporate purposes
---------------	-----------	--	--

15.

- a) Marapharm Las Vegas, LLC paid off the existing mortgage on the 5.9 acres in Apex Business Park in the amount of \$297,091.92.
- b) Marapharm Las Vegas, LLC paid \$111,150.00 for the additional 1.17 acres in Apex Business Park (as described in 7. (c))

16.

- Marapharm has established a Management Advisory Group (MAG) and is planning to appoint up to five members in order to provide professional guidance to management.

17.

- With regard to Nevada, legalization of recreational marijuana received a “yes” vote during the November 2016 presidential elections in the United States.
- With regard to Washington, Washington State has dismantled the medical marijuana initiative (I-692) in favor of the more regulated I-502. This removes the medical marijuana cultivators but allows medical dispensaries to dispense medical and recreational marijuana. As a result of these regulatory changes, marijuana sales in Washington have broken all prior records over the last 4 months.
- The Prime Minister of Canada has announced the legalization of recreational marijuana for 2017.

Dated: March 3, 2017

*“Linda Sampson”*

\_\_\_\_\_  
Lind Sampson  
Chief Executive Officer